Spotlight
Money Desk
Obituaries
Classifieds
Families First
News
Weather
Specialists
Sports
Business
Opinion
Consumer
Health
Life
Out & About
Login
Recommended
Police say violent crime improving in downtown Raleigh, but more work is needed
Recommended
Cyclospora parasite illnesses have affected 28 NC counties, sickened more than 200 people
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WRALTechWire 30
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Melt Pharmaceuticals, Inc.
Melt Pharmaceuticals Announces First Patient Dosed in Pivotal Phase 3 Program of Its Lead Product Candidate, MELT-300, for Needle- and Opioid-Free Sedation in Patients Undergoing Cataract Surgery
June 06, 2024
From
Melt Pharmaceuticals, Inc.
Via
Business Wire
Tickers
HROW
Melt Pharmaceuticals Closes $24 Million Series B Preferred Stock Financing
April 02, 2024
From
Melt Pharmaceuticals, Inc.
Via
Business Wire
Tickers
HROW
Melt Pharmaceuticals Provides Corporate Update
January 03, 2024
From
Melt Pharmaceuticals, Inc.
Via
Business Wire
Tickers
HROW
Melt Pharmaceuticals Announces Exclusive Development and License Agreement with Catalent for Its Zydis® Fast-Dissolve Technology for Use in MELT-300 for Needle- and Opioid-Free Procedural Sedation
September 26, 2023
From
Melt Pharmaceuticals, Inc.
Via
Business Wire
Tickers
HROW
Melt Pharmaceuticals’ MELT-300 (Midazolam 3mg and Ketamine 50mg Sublingual Tablet) Achieves Primary Sedation Endpoint in Phase 2 Pivotal Efficacy and Safety Study
December 21, 2022
From
Melt Pharmaceuticals, Inc.
Via
Business Wire
Tickers
HROW
Melt Pharmaceuticals Announces Dosing of Last Patient in Phase 2 Pivotal Efficacy and Safety Study for MELT-300
October 27, 2022
From
Melt Pharmaceuticals, Inc.
Via
Business Wire
Tickers
HROW
Melt Pharmaceuticals Announces MELT-210 Top-Line Results of Phase 1 Pharmacokinetics (PK) Study for Procedural Sedation
May 04, 2022
From
Melt Pharmaceuticals, Inc.
Via
Business Wire
Tickers
HROW
Melt Pharmaceuticals Submits INDs for MELT‑210 and MELT-400 to FDA
January 04, 2022
From
Melt Pharmaceuticals, Inc.
Via
Business Wire
Tickers
HROW
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.